Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Milestone payment results in further profitability in fiscal year 2015, continuing the trend from 2014 - 17/12/2015

    Phenex AG reaches milestone in collaboration with Janssen

    Phenex Pharmaceuticals AG (Phenex) today announced the achievement of a milestone in the collaboration with Janssen Biotech, Inc. (Janssen), which triggers a 6 M US$ payment by Janssen. In late 2012, Phenex and Janssen entered into a research collaboration on RORgt with a view to develop new therapeutic approaches for chronic inflammatory and autoimmune diseases.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/phenex-ag-reaches-milestone-in-collaboration-with-janssen
  • Telemedizin - 19/10/2015 User interface of a social medical application platform.

    SMARTY – a new way to treat and care for chronically ill children

    Chronic and complex diseases in children are often a heavy burden on their families. Parents naturally want their children to have the latest treatment, and children are usually treated by several specialists. This makes it rather difficult, or, at the very least, involves considerable effort to keep everyone up to date. Dr. Joachim Riethmüller from the University Children’s Hospital in Tübingen and his team of doctors are using telemedicine in…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/smarty-a-new-way-to-treat-and-care-for-chronically-ill-children
  • Article - 27/07/2015 Zender_Lars_Prof.jpg

    Looking for the Achilles’ heel of the tumour

    Although medicines that inhibit the growth of cancer cells are available, the prognosis for patients with solid tumours is generally still rather poor. The reason for this is that tumour cells develop resistance to therapy during treatment, and the tumour can continue to grow. However, tumours are vulnerable – if only more robust medicines were available. Prof. Dr. Lars Zender, senior physician and head of the Division of Translational…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/looking-for-the-achilles-heel-of-the-tumour
  • Article - 20/07/2015 23437_de.jpg

    Liver cell carcinoma: reducing tumour burden – increasing life expectancy

    Liver cell carcinoma or hepatocellular carcinoma (HCC) is one of the most malignant human cancers. The disease arises from chronic damage to the liver, usually caused by virus- or alcohol-related liver cirrhoses. Liver tumours are considered difficult to treat, but there is evidence that they actually trigger an immune response in the body. Prof. Dr. Robert Thimme from Freiburg University Medical Centre is seeking to understand this effect and…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/liver-cell-carcinoma-reducing-tumour-burden-increasing-life-expectancy
  • Overview

    Red biotechnology

    The latest articles, press releases and dossiers on red biotechnology in Baden-Württemberg

    https:////www.gesundheitsindustrie-bw.de/en/article/biotech
  • Article - 16/03/2015 Microscopic image of liver tissue. The area in the centre of the image has an intense yellow-red colour.<br />

    The critical balance between liver fibrosis and liver regeneration

    When the liver has been damaged, a receptor protein of the hepatic stellate cells called endosialin controls the balance between liver repair and scar formation. A team of researchers from Heidelberg and Mannheim has shown that endosialin is a positive regulator of fibrogenesis and a negative regulator of hepatocyte proliferation. Endosialin therefore seems to be a promising therapeutic drug target in non-neoplastic settings.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-critical-balance-between-liver-fibrosis-and-liver-regeneration
  • Press release - 09/03/2015 Phenex Logo

    Gilead Sciences aquires FXR-program of Phenex Pharmaceuticals AG

    Gilead Sciences, Inc. (Foster City, CA, U.S.A.) and Phenex Pharmaceuticals AG (Ludwigshafen/Heidelberg, Germany), a privately-held biotechnology company, announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH).

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/gilead-sciences-aquires-fxr-program-of-phenex-pharmaceuticals-ag
  • Dossier - 09/03/2015 22868_de.jpg

    Advances in the study and treatment of liver diseases

    Liver diseases are often underestimated despite being quite common and potentially having serious and even life-threatening consequences, especially in chronic cases. The most common causes of liver diseases are hepatitis viruses, excessive alcohol consumption, and obesity; congenital or autoimmune liver diseases are quite rare. Thanks to advances in medical research, diseases such as hepatitis B and C can be treated effectively. Fewer advances…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/advances-in-the-study-and-treatment-of-liver-diseases
  • Article - 22/12/2014 22598_de.jpg

    Fighting hepatitis viruses with their own weapons

    Virologist Prof. Dr. Stephan Urban from the University of Heidelberg has been awarded the DZIF Prize for Translational Infection Research for the discovery and development of a promising peptide drug for the treatment of hepatitis B virus infections. The peptide prevents viruses from entering the liver cells, and is also effective against hepatitis D infection. Hepatitis D is the deadliest of all viral liver diseases and no specific antiviral…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/fighting-hepatitis-viruses-with-their-own-weapons
  • Article - 15/12/2014 Schematic showing how cardiac muscle cells are prepared, and how cell nuclei and the genetic material are isolated.

    Heart muscle cell 1.0 and 2.0 – two epigenetic programmes in one cell

    All the cells in an organism have to adapt to changing requirements as they develop and grow - including muscle cells in the heart. Crucial to this process are the cells’ growth in size and epigenetic factors that play a role in modulating the expression of various genes. The role of epigenetics in cancer development has been the focus of research for quite some time. The question is, what role do epigenetic factors play in the development of the…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/heart-muscle-cell-1-0-and-2-0-two-epigenetic-programmes-in-one-cell
  • Article - 13/10/2014 21907_de.jpg

    Data mining is likely to play an increasing role in clinical development

    Data mining still plays a minor role in the research-based pharmaceutical industry. But this is likely to change in the future. Mathematician Hans-Jürgen Lomp predicts that exploratory data analysis will be used to a greater extent in the future. Lomp is the Global Head of Statistics in Boehringer Ingelheim Pharma GmbH & Co KG’s Department of Medical Data Service and Biostatistics in Biberach.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/data-mining-is-likely-to-play-an-increasing-role-in-clinical-development
  • Article - 15/09/2014 21978_de.jpg

    Mesenchymal stromal cells: promising cell therapy candidates

    Mesenchymal stromal cells MSC are increasingly moving into the spotlight as the beacon of hope for somatic cell therapies. The biomedical research community is currently carrying out more than 300 clinical trials to investigate their suitability for a broad range of indications. Prof. Schrezenmeier professor of transfusion medicine and medical director at the Institute for Clinical Transfusion Medicine and Immunogenetics IKT in Ulm is involved in…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/mesenchymal-stromal-cells-promising-cell-therapy-candidates
  • Article - 25/08/2014 The photo shows a model vertebra and an applicator attached to it. Such models are used to test different materials as well as their positioning and application.

    Frederik Wenz - radiologist sets milestone with new surgical technique for the treatment of bone metastases

    Can painful bone metastases be treated in a targeted and quick way? Can metastases that are potentially present in the liver and kidneys be adequately treated at the same time as bone metastases? These are the questions that Professor Dr. med. Frederik Wenz from the University Medical Center Mannheim asked himself before going on to develop an innovative surgical technique. After a long development period, this technique is now recognized as an…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/frederik-wenz-radiologist-sets-milestone-with-new-surgical-technique-for-the-treatment-of-bone-metas
  • Dossier - 31/03/2014 Structural formula of a dipeptide, which is the shortest possible peptide.

    Peptides – diverse molecules of life

    Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Despite some drawbacks, peptides are gaining in importance as candidates for drugs…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
  • Article - 26/03/2014 21246_de.jpg

    CeloNova is taking off

    CeloNova BioSciences is a global medical device company whose core technology is currently mainly used for interventional cardiology (stents) and tumour embolisation (selective occlusion of tumour arteries) products. The company has been expanding since 2010. CeloNova products are currently available in 52 countries and there are plans to place them on the Asian market in 2014 and further increase company turnover.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/celonova-is-taking-off
  • Dossier - 10/03/2014 20939_de.jpg

    Cancer therapy and cancer diagnostics

    Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
  • Article - 29/07/2013 20163_de.jpg

    Food supplements from blue-green algae do more harm than good

    Dietary supplements containing different types of algae claim to be rich in minerals that help improve mental acuity and concentration. While many of these products are neither useful nor harmful, products containing blue-green algae have raised serious concerns. Consumers have repeatedly complained about pain and discomfort after consumption. A study carried out by toxicologist Prof. Dr. Daniel Dietrich from the University of Konstanz has now…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/food-supplements-from-blue-green-algae-do-more-harm-than-good
  • Dossier - 13/05/2013 19501_de.jpg

    The human proteome – the next major goal

    The “Human Proteome Project”, a ten-year global initiative that is making a systematic effort to map all human proteins, has moved from the planning to the experimental stage. How significant and how effective the project will be depends on how much the resources offered are used by proteome researchers and on the data that the researchers bring into the project.

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/the-human-proteome-the-next-major-goal
  • Article - 15/04/2013 19462_de.jpg

    Molecule-specific diagnosis of metabolic diseases

    In cooperation with the company Centogene AG Prof. Dr. Michael Przybylski from the Steinbeis Transfer Center for Biopolymer Analysis and Biomolecular Mass Spectrometry at the University of Konstanz has developed a method that involves a novel substance class and enables the parallel measurement of enzyme activity based on fluorometry and mass spectroscopy. The method for which the inventors have recently filed a patent application forms the basis…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/molecule-specific-diagnosis-of-metabolic-diseases
  • Article - 08/04/2013 19469_de.jpg

    The first major cell migration

    It is of crucial importance that cells stick tightly together where their function requires them to do so for example in organs such as the heart and the liver to name but two examples. However it is equally crucial that cells start to migrate at some stage during embryonic development in order to form such organs. Prof. Dr. Wolfgang Driever from the Institute of Biology I at the University of Freiburg and his team have elucidated the molecular…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-first-major-cell-migration
  • Article - 28/01/2013 19105_de.jpg

    Epigenetics and childhood blood cancer

    Juvenile myelomonocytic leukaemia JMML is the most common chronic cancer of the blood in children and tends to have a poor response to chemotherapy. Prof. Dr. Christian Flotho and his team from the Centre of Paediatric and Adolescent Medicine in Freiburg have shown that epigenetic mechanisms play a key role in the pathogenesis of JMML. As part of a German Research Foundation priority programme the researchers from Freiburg are working on…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/epigenetics-and-childhood-blood-cancer
  • Article - 07/01/2013 19006_de.jpg

    HepaChip: a promising tool for assessing adverse drug effects

    Liver damage is one of the most common adverse drug effects. Since results obtained with animal experiments can only be transferred to the situation in humans to a limited extent, there is a need for cell-based systems that model human organ function as closely as possible. The new HepaChip, developed by researchers at the NMI in Reutlingen on the basis of human liver and endothelial cells is able to do just this.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/hepachip-a-promising-tool-for-assessing-adverse-drug-effects
  • Article - 17/12/2012 18923_de.jpg

    Medicyte GmbH – gold standard for human cells

    Medicyte GmbH is a life sciences company located in the city of Heidelberg. It focuses primarily on the production of quasi-primary human cells of the highest quality and in virtually unlimited quantity. MediCyte’s goal is to establish its proprietary cell proliferation technologies as gold standard for the use of human cells and cell products in research, development and cell therapy.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/medicyte-gmbh-gold-standard-for-human-cells
  • Dossier - 05/11/2012 18550_de.jpg

    Cancer – basic research, successes and trends

    Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer. This…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-basic-research-successes-and-trends
  • Article - 22/10/2012 Parametric representation of liver tissue using PIViewer®. Intensity-time curves can be produced from any image point and turned into a parameter image in off-colours (right). Here, the coding aspects of the course of the curve are represented with a freely defined fit function. The parameter image shows the differences between healthy liver tissue (top signalling curve) and metastases (bottom signalling curve) in take up of the contrast agent.

    syneed imaging: precise visualisation of functional tissue properties

    Functional medical imaging modalities are of great significance in modern medical diagnostics. Existing ways of diagnosing diseases are now being expanded with the arrival of the innovative parameter imaging method. syneed imaging uses proprietary highly sensitive software for the analysis of dynamic image data. This software complements standard methods such as computed tomography and magnetic resonance imaging and increases the significance of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/syneed-imaging-precise-visualisation-of-functional-tissue-properties

Page 2 / 6

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • sb_theme_biopro.domain.mdr-ivdr
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search